Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $24,892.14 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 546 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $45.59, for a total value of $24,892.14. Following the sale, the chief executive officer now owns 672,518 shares in the company, valued at approximately $30,660,095.62. The trade was a 0.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Twist Bioscience Price Performance

NASDAQ TWST traded down $2.89 during trading hours on Tuesday, reaching $45.62. The company’s stock had a trading volume of 814,483 shares, compared to its average volume of 657,996. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -12.67 and a beta of 1.85. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The company’s 50-day moving average is $46.16 and its two-hundred day moving average is $46.51.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently bought and sold shares of TWST. State Street Corp increased its stake in Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after buying an additional 526,028 shares in the last quarter. Geode Capital Management LLC increased its stake in Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after buying an additional 26,145 shares in the last quarter. Thrivent Financial for Lutherans purchased a new stake in Twist Bioscience during the 3rd quarter worth approximately $43,992,000. Wellington Management Group LLP increased its stake in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares in the last quarter. Finally, Fred Alger Management LLC increased its stake in Twist Bioscience by 17.1% during the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock worth $34,660,000 after buying an additional 112,272 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TWST. Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Evercore ISI boosted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Scotiabank boosted their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, TD Cowen reissued a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.